Tocolytic Use
Tocolytic Use - Related Videos
09:24
Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
0 Views •
Cited by 14 •
2019
Three-dimensional co-culture spheroid angiogenesis assay system is designed to mimic the physiologic angiogenesis. Co-culture spheroids are formed by two human vascular cell precursors, ECFCs and MSCs, and embedded in collagen gel. The new system is effective for evaluating angiogenic modulators, and provides more relevant information to the in vivo study.
14:10
Separation and Identification of Conventional Microplastics from Farmland Soils
0 Views •
Cited by 4 •
2025
Presented here is a method for extracting microplastics from soil and identifying their polymer types. The method has been optimized for execution, applicability, and cost-effectiveness. It lays a scientific foundation for standardizing the analytical method to identify microplastics in soils.
09:23
JenaTron - An Experimental Approach to Study the Effects of Plant History and Soil History on Grassland Ecosystem Functioning
0 Views •
Cited by 2 •
2025
Here we present a study established in the iDiv Ecotron, terrestrial mesocosm chambers with controlled environmental conditions above- and below-ground, to study the independent and interactive effects of plant history and soil history on ecosystem functioning of grassland communities along a plant diversity gradient.
FAQs
The main pathways differ in what they target within uterine smooth-muscle cells. Oxytocin-receptor blockade limits oxytocin-related stimulation, calcium-entry reduction restricts a cellular process needed for contraction, and reduced prostaglandin production lowers another contraction-promoting influence. These distinctions explain why medications can suppress contractions through different pharmacologic routes.
Mechanism alone does not determine the best option. Although each pathway can limit uterine contraction, the expected benefits and maternal or fetal risks vary with the medication and the clinical condition. Consequently, clinicians must weigh the pharmacologic target against the circumstances of the pregnancy rather than treating all episodes with an identical drug strategy.
A short delay can function as a time-sensitive bridge to other aspects of obstetric care. It may provide time for antenatal corticosteroids to support fetal lung maturation, magnesium sulfate for fetal neuroprotection when indicated, or transfer to a facility with specialized neonatal care. The benefit therefore comes from using the interval purposefully, not simply from postponing birth.
Before and during treatment, clinicians perform careful clinical assessment and maintain monitoring because the balance of benefit and risk can change with the medication and the maternal or fetal condition. The process is not simply administration followed by observation; ongoing evaluation helps determine whether the intended short delay remains appropriate.
Transfer becomes a relevant application when additional time could allow the pregnant patient to reach a facility equipped for specialized neonatal care. Suppressing contractions temporarily may create that opportunity, while the clinical team continues to assess maternal and fetal considerations. In this setting, the medication supports logistical and clinical preparation rather than serving as a standalone solution.
The expected outcome is useful additional time, not a permanent resolution of the risk associated with preterm birth. That interval may support fetal lung maturation, neuroprotection when indicated, or movement to specialized neonatal care. Viewing the result as temporary helps place contraction suppression within a broader obstetric plan and explains why monitoring remains essential.